Amgen Stock Forecast, Price & News

Amgen's stock was trading at $198.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AMGN stock has increased by 27.0% and is now trading at $252.36.
View which stocks have been most impacted by COVID-19.

30 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 12 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Amgen stock.
View analyst ratings for Amgen or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Amgen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amgen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

1,428 employees have rated Amgen CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Amgen's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, February 2nd 2021.
View our earnings forecast for Amgen.

Amgen will be holding an earnings conference call on Tuesday, February 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Amgen Inc. (NASDAQ:AMGN) issued its quarterly earnings data on Monday, November, 2nd. The medical research company reported $4.37 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $3.75 by $0.62. The medical research company earned $6.42 billion during the quarter, compared to analysts' expectations of $6.38 billion. Amgen had a net margin of 29.42% and a return on equity of 95.55%.
View Amgen's earnings history.

Amgen announced a quarterly dividend on Wednesday, December 16th. Stockholders of record on Monday, February 15th will be given a dividend of $1.76 per share on Monday, March 8th. This represents a $7.04 annualized dividend and a yield of 2.79%. The ex-dividend date of this dividend is Thursday, February 11th. This is a positive change from Amgen's previous quarterly dividend of $1.60.
View Amgen's dividend history.

Amgen pays an annual dividend of $6.40 per share and currently has a dividend yield of 2.58%. Amgen does not yet have a strock track record of dividend growth. The dividend payout ratio of Amgen is 43.18%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Amgen will have a dividend payout ratio of 37.65% next year. This indicates that Amgen will be able to sustain or increase its dividend.
View Amgen's dividend history.

Amgen issued an update on its FY20 earnings guidance on Wednesday, October, 28th. The company provided EPS guidance of $15.80-16.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $15.78. The company issued revenue guidance of $25.1-25.5 billion, compared to the consensus revenue estimate of $25.39 billion.

30 brokerages have issued 12-month target prices for Amgen's stock. Their forecasts range from $185.00 to $304.00. On average, they anticipate Amgen's share price to reach $255.88 in the next twelve months. This suggests a possible upside of 1.4% from the stock's current price.
View analysts' price targets for Amgen or view Wall Street analyst' top-rated stocks.

Some companies that are related to Amgen include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Novavax (NVAX) and United Therapeutics (UTHR).
View all of AMGN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), The Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and The Home Depot (HD).

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Sarasin & Partners LLP (0.18%), Bartlett & Co. LLC (0.07%), Gateway Investment Advisers LLC (0.04%), Cullinan Associates Inc. (0.03%), Boston Trust Walden Corp (0.03%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams and Ronald D Sugar.
View institutional ownership trends for Amgen.

AMGN stock was sold by a variety of institutional investors in the last quarter, including RNC Capital Management LLC, Pacer Advisors Inc., State of Alaska Department of Revenue, Exchange Traded Concepts LLC, Transform Wealth LLC, American National Bank, Pinnacle Financial Partners Inc., and Huntington National Bank. Company insiders that have sold Amgen company stock in the last year include David Piacquad, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen or view top insider-selling stocks.

AMGN stock was acquired by a variety of institutional investors in the last quarter, including Sarasin & Partners LLP, Crossmark Global Holdings Inc., Chesley Taft & Associates LLC, Louisiana State Employees Retirement System, Oak Harvest Investment Services, Boston Trust Walden Corp, Wedge Capital Management L L P NC, and Bennicas & Associates Inc..
View insider buying and selling activity for Amgen or or view top insider-buying stocks.

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMGN stock can currently be purchased for approximately $252.36.

Amgen has a market capitalization of $146.92 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe.

The official website for Amgen is www.amgen.com.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]